查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1827132

全球遺傳學市場（按技術、測試類型、應用、最終用戶和產品類型）預測​​ 2025-2032

Predictive Genetics Market by Technology, Test Type, Application, End User, Product Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年預測遺傳學市場將成長 58.8 億美元，複合年成長率為 18.83%。

主要市場統計數據
基準年2024年 14.7億美元
預計2025年 17.5億美元
預測年份：2032年 58.8億美元
複合年成長率（%） 18.83%

在技​​術進步、道德要求、監管限制和相關人員商業化優先事項的框架內策略性地採用預測遺傳學

預測遺傳學處於基因組學、臨床實踐和商業性創新的交叉領域。群體定序、分析流程和生物資訊學的進步，已經改變了醫療保健和生命科學領域相關人員預測疾病風險、指導治療方法選擇以及設計人群篩檢方案的方式。因此，從實驗室營運商到付款方再到平台提供商，相關人員必須重新調整其策略，以反映從被動診斷到預防性和預測性護理模式的加速轉變。

高通量技術和模組化服務的引入降低了進入門檻，同時也提高了對分析嚴謹性、資料管治和臨床有效性的期望。因此，決策者需要可操作的情報，以闡明技術差異化、特定應用的價值提案以及不斷變化的監管和報銷格局。此外，圍繞知情同意、公平獲取和演算法透明度的倫理考量對於公眾認知和政策回應都日益重要。

本介紹總結了當前的環境，並為更深入的部分奠定了基礎，這些部分分析了變革性變化、關稅的影響、細分動態、區域細微差別、公司層面的策略等。透過確定關鍵促進因素和限制因素，介紹列出了相關人員必須解決的策略挑戰，以將預測遺傳學的進步轉化為永續的臨床和商業性成果。

技術民主化、監管演變和綜合護理模式的融合如何再形成基因預測生態系統和商業性策略

預測遺傳學的格局正在被各種力量再形成，這些力量加速了臨床應用，同時也使商業化變得更加複雜。技術民主化，以更廉價的定序、更複雜的檢測化學和雲端分析為特徵，正在擴大可尋址的臨床用例，同時也在分化供應商生態系統。同時，支付方和醫療系統要求提供臨床效用和成本效益的有力證據，這促使供應商轉向標準化、經過驗證的工作流程和更強大的結果檢驗。

同時，法律規範也在不斷發展，以應對複雜的基因組輸出、演算法主導的風險評分以及跨境資料流。雖然監管的成熟提高了可預測性，但也提高了新平台和直接面對消費者產品的市場准入成本。圍繞公平獲取和知情同意的倫理辯論仍然至關重要，這迫使開發者和臨床合作夥伴將管治通訊協定和社區參與實踐制度化。

最後，市場動態青睞整合了高品質檢測、解讀服務和檢測後諮詢的整合解決方案，以實現更優質的端到端患者病人歷程。儀器製造商、定序服務供應商、臨床實驗室和軟體供應商之間的策略合作正成為擴展檢驗服務的主要機制。這種變革性轉變凸顯了靈活應變的經營模式、有針對性的臨床證據產生以及積極主動的監管和支付方參與的必要性，以實現預測遺傳學的前景。

了解 2025 年美國關稅調整對遺傳學預測供應鏈和定價動態的營運、採購和競爭影響

美國2025年關稅變化將為整個基因預測價值鏈的營運和採購決策帶來新的變數。某些試劑和設備組件的進口關稅上調可能會影響實驗室和定序中心的成本結構，促使其重新評估籌資策略和庫存管理。為此，許多機構正在評估近岸外包機會、替代供應商和長期契約，以降低貿易主導的價格波動所帶來的風險。

進口限制也影響了競爭格局，有利於擁有國內製造能力的垂直整合供應商，同時擠壓依賴進口耗材和專用設備的小型服務實驗室。因此，供應商可能會優先投資於供應鏈彈性，例如認證多家供應商、增加安全庫存以及投資於能夠相容於更多試劑的模組化平台。

除了對採購的直接影響外，關稅主導的成本壓力還可能改變與付款人和客戶的價格談判，增強對營運效率的關注，並加速中小企業的整合。因此，相關人員應密切關注關稅政策的發展，量化產品和服務線的風險敞口，並主動與供應商和客戶溝通，溝通潛在影響和緩解措施。

全面的細分洞察，揭示技術、測試類型、應用程式、最終用戶和產品類型如何交叉以定義商業機會和策略重點

細緻的細分視角可以明確價值創造的領域以及哪些途徑需要差異化策略。從技術角度來看，微陣列平台仍然適用於群體層級的檢測，並細分為比較基因組雜合反應和表達微陣列方案，而次世代定序包括標靶定序、全外EXOME定序和全基因組定序，以適應不同深度和廣度的研究。考慮到測試類型，癌症篩檢為 BRCA 檢測、大腸直腸癌篩檢和肺癌篩檢提供了不同的臨床和商業性軌跡；攜帶者篩檢範圍從擴展面板到單基因攜帶者檢測；藥物基因組學包括與處方工作流程緊密結合的 CYP 和藥物代謝測試；產前檢測區分侵入性和非侵入神經退化風險整合

基於應用的細分顯示，預測遺傳學在心血管疾病（如心臟病和中風）、感染疾病監測和疫情應對、神經系統疾病、腫瘤學（包括乳癌、結直腸癌和肺癌等子領域）以及診斷產量至關重要的罕見疾病中發揮著重要作用。最終用戶包括學術研究機構、診斷實驗室、直接面對消費者的管道和醫院，每個用戶都有不同的購買週期、檢驗要求和上市時間預期。產品類型包括消耗品、儀器、服務和軟體。服務包括遺傳諮詢、定序服務和檢測服務，其中定序服務值得特別關注，因為它們細分為 NGS 和 PCR 服務。總之，這些細分層告知應優先考慮證據產生、產品開發和商業投資，以使技術能力與臨床工作流程和付款人期望保持一致。

亞太地區、歐洲、中東和非洲的區域動態和監管細微差別決定了招募途徑、報銷和營運重點

區域動態在塑造預測遺傳學領域的需求、報銷途徑和監管預期方面發揮著至關重要的作用。在美洲，強勁的私人支付市場和活躍的直接面對消費者的管道正在支持臨床導向檢測的快速普及，但報銷政策的差異性使得在關鍵治療領域開展有針對性的證據開發成為必要。同時，歐洲、中東和非洲的國家管理體制和公共衛生優先事項各不相同。在某些地區，集中監管協調與國家報銷差異並存，使得區域衛生經濟模式和相關人員的參與對於市場進入和擴張至關重要。

亞太地區多元化的醫療保健架構和對基因組研究的強勁公共投資，既帶來了市場進入機遇，也帶來了營運複雜性。有些市場優先考慮全民篩檢和國家基因組策略，而有些市場則是新興市場，有報銷限制。跨地區比較分析顯示，監管時間表、數據在地化要求和採購慣例存在顯著差異，這迫使企業在不同地區調整其定價、證據和夥伴關係方式。最後，區域人才庫、實驗室認證標準和供應鏈佈局會影響製造、服務中心和研究合作的選址，這進一步凸顯了區域特定策略規劃的重要性。

競爭動態和公司層面的策略結合技術差異化、服務整合、夥伴關係和證據產生來獲得預測遺傳學的價值

基因預測領域的競爭優勢取決於技術領先地位、服務整合以及透過檢驗證據證明臨床價值的能力。主要企業正在採取不同的方法：一些公司專注於儀器創新和專有化學技術，以確保耗材收益來源；另一些公司專注於軟體和解讀平台，以獲取下游利潤並實現多組體學整合；實驗室網路和定序服務供應商透過標準化工作流程和擴大地理覆蓋範圍來實現規模化。連接儀器製造商和臨床實驗室、軟體供應商和生物製藥公司、諮詢服務機構和付款人的策略夥伴關係關係和跨部門聯盟，正成為提供端到端解決方案日益重要的機制。

智慧財產權和監管核准仍然是差異化因素，尤其對於伴隨診斷和與報銷驅動適應症相關的檢測。投資於以患者為中心的服務（例如綜合遺傳諮詢和長期結果追蹤）的公司更有能力滿足付款人對已證實效用的期望。隨著大型公司收購利基技術、解讀能力或區域偵測能力以加速市場進入，併購正在持續重塑市場格局。總體而言，競爭成功將取決於能否將技術差異化與檢驗的臨床路徑、可擴展的營運以及完善的資料管治框架相結合。

為行業領導者提供可操作且實用的建議，以協調夥伴關係、證據策略、供應鏈彈性和數據管治與可擴展的商業化計劃

行業領導者應採取多管齊下的務實方法，在管理風險的同時實現成長。首先，優先發展將檢測與解讀和諮詢服務相結合的策略合作夥伴關係，從而創造符合臨床工作流程、價值更高、黏性更強的產品。其次，投資符合付款人要求和區域醫療技術援助框架的有針對性的臨床證據項目。在優先適應症中展示療效改善和成本抵消，以降低進入門檻並支持報銷談判。第三，透過供應商多元化、可行的試劑替代品以及選擇性近岸外包來增強供應鏈的韌性，以緩解關稅和物流中斷的影響。

此外，建立嚴格的資料管治和隱私實踐對於維護信任和滿足不斷變化的監管期望至關重要。這包括透明的知情同意流程、安全的分析環境以及公平的存取機制。公司還應評估將直接面對消費者和臨床醫生中介管道相結合的混合商業模式，以在保持臨床監管的同時擴大覆蓋範圍。最後，領導者必須致力於員工發展和臨床教育計劃，以提高臨床醫生和付款人的基因素養，促進適當的檢測利用，並減少實施過程中的摩擦。

一種透明的混合調查方法，結合專家訪談、二次證據綜合、分割映射和強大的檢驗通訊協定

本研究採用混合調查方法，整合了主要研究和次要研究。主要輸入包括與臨床負責人、實驗室主任、付款人和技術供應商的結構化訪談，並輔以檢驗訪談以檢驗新出現的假設。次要分析涵蓋同行評審文獻、監管指南、臨床實踐指南和行業技術簡報，以確認概念與現行標準一致。資料三角測量技術可協調不同的觀點，並檢驗不同資訊來源的主題結論。

分析方法包括細分圖譜、技術就緒評估、監管路徑分析和基於情境的敏感度評估。品管包括資訊來源三角測量、受訪者檢驗和內部同行評審，以確保穩健性並減少偏差。我們承認調查方法有局限性，例如各國報銷實踐的差異和快速發展的法規環境。在適用的情況下，我們會將研究結果具體化，而不是將其視為通用處方箋。最後，建議基於可重複的分析步驟，使相關人員能夠根據其特定的地理、治療領域或商業性環境調整此框架。

關於綜合解決方案、本地化策略、供應鏈彈性和基於證據的參與如何決定遺傳學預測成功的總結

基因預測正從願景轉化為行動，但要充分發揮其潛力，需要在技術、證據生成和相關人員參與方面進行有針對性的協調。本報告始終貫穿著一個主題：結合高品質檢測、嚴謹解讀和以患者為中心的服務的整合解決方案，在臨床應用和付款人接受度方面將優於單點解決方案。此外，地理和監管的細微差別要求我們採取量身定做的方法，而非一刀切的部署方式，而諸如關稅變化等供應鏈動態可能會對營運可行性產生重大影響。

展望未來，那些能夠展現臨床和經濟價值、保持靈活且富有彈性的籌資策略並投資於透明管治以維護信任的組織將會取得成功。策略夥伴關係和有針對性的證據項目將加速其應用，而員工培訓和臨床醫生的參與將減少應用過程中的摩擦。總而言之，預測遺傳學的擴展之路將取決於將技術創新與現實世界的臨床工作流程、報銷現實和負責任的資料管理相結合。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 將多基因風險評分整合到常規臨床決策支援工作流程中以預防慢性疾病
  • 擴展直接面對消費者的基因檢測平台，透過人工智慧解讀提供血統和健康風險洞察
  • 利用藥物基因組學分析個人化腫瘤治療方法並減少癌症治療的藥物不良反應
  • 奈米孔定序的進步使得公共衛生環境中的即時病原體監測和疫情預測成為可能
  • 基因組學Start-Ups與遠端醫療提供者建立策略合作夥伴關係，提供 DNA檢測套組和居家諮詢
  • 實施符合 GDPR 的基因組資料共用框架，促進跨國研究合作
  • 採用區塊鏈技術提高基因數據管理和患者同意的安全性和透明度

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 預測遺傳學市場（按技術）

  • 微陣列
    • 比較基因組雜合反應
    • 表達微陣列
  • 次世代定序
    • 標靶定序
    • 全EXOME定序
    • 全基因測序
  • 聚合酵素鏈鎖反應
    • 數位PCR
    • 即時PCR
  • 桑格定序

9. 預測遺傳學市場（按測試類型）

  • 癌症篩檢
    • BRCA檢測
    • 大腸癌篩檢
    • 肺癌篩檢
  • 攜帶者篩檢
    • 延長航母
    • 單基因攜帶者
  • 藥物基因組學
    • CYP檢測
    • 藥物代謝檢測
  • 產前檢查
    • 侵入性產前檢測
    • 非侵入性產前檢測
  • 風險評估
    • 心血管風險
    • 神經退化風險

第 10 章預測遺傳學市場（按應用）

  • 心血管系統
    • 心臟病
    • 中風
  • 感染疾病
  • 神經系統疾病
  • 腫瘤學
    • 乳癌
    • 大腸直腸癌
    • 肺癌
  • 罕見疾病

第 11 章預測遺傳學市場（按最終用戶）

  • 學術研究機構
  • 診斷實驗室
  • 消費者
  • 醫院

第 12 章預測遺傳學市場（依產品類型）

  • 耗材
  • 裝置
  • 服務
    • 遺傳諮詢
    • 定序服務
      • NGS服務
      • PCR服務
    • 測試服務
  • 軟體

第13章預測遺傳學市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 14 章預測遺傳學市場（按群體）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章。按國家/地區分類的預測遺傳學市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Myriad Genetics, Inc.
    • Invitae Corporation
    • Natera, Inc.
    • 23andMe Holding Co.
    • Fulgent Genetics, Inc.
    • Guardant Health, Inc.
    • Color Health, Inc.
    • Helix OpCo, Inc.
    • Gene by Gene, Ltd.
    • Genomic Prediction, Inc.
Product Code: MRR-8903005C49A9

The Predictive Genetics Market is projected to grow by USD 5.88 billion at a CAGR of 18.83% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.47 billion
Estimated Year [2025] USD 1.75 billion
Forecast Year [2032] USD 5.88 billion
CAGR (%) 18.83%

A strategic introduction to predictive genetics that frames technological advances, ethical imperatives, regulatory constraints, and commercialization priorities for stakeholders

Predictive genetics stands at the intersection of genomic science, clinical practice, and commercial innovation. Advances in sequencing, analytical pipelines, and bioinformatics have transformed how actors across healthcare and life sciences anticipate disease risk, guide therapeutic choices, and design population-level screening programs. As a result, stakeholders from laboratory operators to payers and platform providers must recalibrate strategy to reflect an accelerating shift from reactive diagnosis to preventive and predictive care models.

The introduction of high-throughput technologies and modular service offerings has lowered barriers to entry while raising expectations for analytical rigor, data governance, and clinical validity. Consequently, decision-makers need actionable intelligence that clarifies technology differentiation, application-specific value propositions, and the evolving regulatory and reimbursement landscape. Moreover, ethical considerations around consent, equity of access, and algorithmic transparency are increasingly central to both public perception and policy responses.

This introduction synthesizes the current environment and sets the stage for deeper sections that analyze transformative shifts, tariff impacts, segmentation dynamics, regional nuances, and company-level strategies. By framing key drivers and constraints, this opening establishes the strategic questions stakeholders must address to translate predictive genetics advances into sustainable clinical and commercial outcomes.

How converging technological democratization, regulatory evolution, and integrated care models are reshaping the predictive genetics ecosystem and commercial playbooks

The landscape of predictive genetics is being reshaped by converging forces that accelerate clinical translation even as they complicate commercialization. Technological democratization-characterized by more affordable sequencing, refined assay chemistries, and cloud-enabled analytics-has expanded the addressable clinical use cases while fragmenting the supplier ecosystem. At the same time, payers and health systems are demanding robust evidence of clinical utility and cost-effectiveness, which is driving providers toward standardized validated workflows and stronger outcome data.

Concurrently, regulatory frameworks are evolving to account for complex genomic outputs, algorithm-driven risk scores, and cross-border data flows. This regulatory maturation increases predictability but also raises the cost of market entry for novel platforms and direct-to-consumer offerings. Ethical debates around equitable access and informed consent remain salient, prompting developers and clinical partners to institutionalize governance protocols and community engagement practices.

Finally, market dynamics are favoring integrated solutions that bundle high-quality assays, interpretation services, and post-test counseling, enabling better end-to-end patient journeys. Strategic collaborations between instrument manufacturers, sequencing service providers, clinical laboratories, and software vendors are becoming a primary mechanism to scale validated services. These transformative shifts underscore the need for adaptive business models, targeted clinical evidence generation, and proactive regulatory and payer engagement to realize the promise of predictive genetics.

Understanding the operational, sourcing, and competitive consequences of United States tariff adjustments in 2025 that influence predictive genetics supply chains and pricing dynamics

Tariff changes in the United States during 2025 have introduced a new variable into operational and procurement decisions across the predictive genetics value chain. Increased import duties on certain reagents and instrumentation components can affect cost structures for laboratories and sequencing centers, prompting a reassessment of sourcing strategies and inventory management. In response, many organizations are evaluating nearshoring opportunities, alternative suppliers, and longer-term contracts to mitigate exposure to trade-driven price volatility.

Import constraints also influence the competitive landscape by advantaging vertically integrated suppliers with domestic manufacturing capabilities while pressuring smaller service labs that rely on imported consumables and specialized instruments. Consequently, providers may prioritize investments in supply chain resilience, such as qualifying multiple vendors, increasing safety stock, or investing in modular platforms that accept a broader range of reagents.

Beyond immediate procurement impacts, tariff-driven cost pressures can alter pricing negotiations with payers and clients, intensify the focus on operational efficiency, and accelerate consolidation among smaller players. Therefore, stakeholders should monitor tariff policy developments closely, quantify exposure across product and service lines, and proactively engage suppliers and customers to communicate potential impacts and mitigation strategies.

Comprehensive segmentation insights that reveal how technology, test type, application, end user, and product type intersect to define opportunity and strategic prioritization

A nuanced segmentation lens clarifies where value is created and which pathways demand differentiated strategies. From a technology perspective, microarray platforms remain relevant for population-level assays and are subdivided into comparative genomic hybridization and expression microarray protocols, while next generation sequencing encompasses targeted sequencing, whole exome sequencing, and whole genome sequencing tailored to varying depth and breadth of inquiry; polymerase chain reaction technologies split into digital PCR and real time PCR for high-sensitivity, rapid assays, and legacy Sanger sequencing persists for confirmatory workflows. When considering test type, cancer screening occupies substantial focus with BRCA testing, colorectal cancer screening, and lung cancer screening representing distinct clinical and commercial trajectories; carrier screening ranges from expanded panels to single gene carrier tests, pharmacogenomics includes CYP testing and drug metabolism testing that align tightly with prescribing workflows, prenatal testing differentiates invasive prenatal testing from non invasive prenatal testing, and risk assessment spans cardiovascular risk and neurodegenerative risk applications that require longitudinal data integration.

Application-based segmentation reveals that predictive genetics serves cardiovascular indications such as heart disease and stroke, infectious disease surveillance and outbreak response, neurological disorders, oncology with subdomains like breast cancer, colorectal cancer, and lung cancer, and rare diseases where diagnostic yield is critical. End users include academic research institutes, diagnostic laboratories, direct-to-consumer channels, and hospitals, each with distinct purchasing cycles, validation requirements, and go-to-market expectations. Product types range across consumables, instruments, services, and software; services warrant special attention as they include genetic counseling, sequencing services and testing services, with sequencing service subdivided into NGS service and PCR service. Taken together, these segmentation layers inform where to prioritize evidence generation, product development, and commercial investment to align technical capabilities with clinical workflows and payer expectations.

Regional dynamics and regulatory nuances across the Americas, Europe, Middle East & Africa, and Asia-Pacific that determine adoption pathways, reimbursement, and operational priorities

Regional dynamics play a decisive role in shaping demand, reimbursement pathways, and regulatory expectations across the predictive genetics domain. In the Americas, robust private payer markets and active direct-to-consumer channels drive rapid adoption of clinically oriented assays, yet heterogeneity in coverage policies necessitates targeted evidence generation for key therapeutic areas. Meanwhile, Europe, Middle East & Africa presents a patchwork of national regulatory regimes and public health priorities; centralized regulatory harmonization in some jurisdictions coexists with country-level reimbursement variability, making localized health economic models and stakeholder engagement essential for market entry and scale.

In the Asia-Pacific region, diverse healthcare architectures and substantial public investment in genomic initiatives create both opportunities and operational complexity. Some markets emphasize population-scale screening and national genomics strategies, while others remain nascent with constrained reimbursement. Cross-region comparative analyses highlight that regulatory timelines, data localization requirements, and procurement practices differ materially, so companies must adapt pricing, evidence, and partnership approaches by geography. Finally, regional talent pools, laboratory accreditation standards, and supply chain footprints influence where to site manufacturing, service centers, and research collaborations, reinforcing the importance of geography-specific strategic planning.

Competitive dynamics and company-level strategies that combine technology differentiation, service integration, partnerships, and evidence generation to capture value in predictive genetics

Competitive positioning in predictive genetics is defined by technology leadership, service integration, and the ability to demonstrate clinical value through validated evidence. Key companies are adopting distinct approaches: some focus on instrument innovation and proprietary chemistries to lock in consumable revenue streams, others emphasize software and interpretation platforms to capture downstream margin and enable multi-omic integration, while laboratory networks and sequencing service providers scale by standardizing workflows and expanding geographic reach. Strategic partnerships and cross-sector alliances-linking instrument makers with clinical laboratories, software vendors with biopharma, and counseling services with payers-are increasingly prominent as mechanisms to deliver end-to-end solutions.

Intellectual property and regulatory approvals remain differentiators, particularly for assays tied to companion diagnostics or reimbursement-sensitive indications. Companies investing in patient-centric services, such as integrated genetic counseling and longitudinal outcome tracking, are positioned to meet payer expectations for demonstrated utility. Mergers and acquisitions continue to reconfigure the landscape as larger players acquire niche technologies, interpretation capabilities, or regional laboratory capacity to accelerate market access. Overall, competitive success will hinge on the ability to combine technological differentiation with validated clinical pathways, scalable operations, and robust data governance frameworks.

Actionable and pragmatic recommendations for industry leaders to align partnerships, evidence strategy, supply chain resilience, and data governance with scalable commercialization plans

Industry leaders should adopt a multi-pronged, pragmatic approach to capture growth while managing risk. First, prioritize strategic alliances that integrate assays with interpretation and counseling services, thereby creating higher-value, stickier offerings that align with clinical workflows. Second, invest in targeted clinical evidence programs aligned with payer requirements and local HTA frameworks; demonstrating improved outcomes or cost offsets in priority indications will reduce access barriers and support reimbursement negotiations. Third, reinforce supply chain resilience through supplier diversification, validated alternative reagents, and selective nearshoring to mitigate tariff and logistics disruptions.

Additionally, establishing rigorous data governance and privacy practices will be critical to maintaining trust and meeting evolving regulatory expectations; this includes transparent consent processes, secure analytics environments, and mechanisms for equitable access. Firms should also evaluate hybrid business models that combine direct-to-consumer channels with clinician-mediated pathways to expand reach while maintaining clinical oversight. Lastly, leaders must commit to workforce development and clinical education initiatives to broaden genetics literacy among clinicians and payers, thereby accelerating appropriate test utilization and reducing implementation friction.

Transparent mixed-methods research methodology combining expert interviews, secondary evidence synthesis, segmentation mapping, and robust validation protocols

This research employs a mixed-methods approach that integrates primary qualitative insights with secondary evidence synthesis and methodological triangulation. Primary inputs include structured interviews with clinical leaders, laboratory directors, payers, and technology vendors, supplemented by validation interviews that test emerging hypotheses. Secondary analysis encompasses peer-reviewed literature, regulatory guidance, clinical practice guidelines, and industry technical briefs to ensure conceptual alignment with current standards. Data triangulation methods reconcile divergent viewpoints and validate thematic conclusions across sources.

Analytical techniques include segmentation mapping, technology readiness assessment, regulatory pathway analysis, and scenario-based sensitivity reviews. Quality controls involve source triangulation, respondent validation, and internal peer review to ensure robustness and reduce bias. Limitations of the methodology are acknowledged, including variability in national reimbursement practices and the rapidly evolving regulatory environment; where applicable, findings are contextualized rather than presented as universal prescriptions. Finally, recommendations are grounded in repeatable analytical steps to enable stakeholders to adapt the framework to specific geographies, therapeutic areas, or commercial contexts.

Concluding synthesis of how integrated solutions, tailored regional strategies, supply chain resilience, and evidence-based engagement will determine success in predictive genetics

Predictive genetics is transitioning from promise to practiced utility, but realizing its full potential requires deliberate orchestration across technology, evidence generation, and stakeholder engagement. Throughout this report, a consistent theme emerges: integrated solutions that combine high-quality assays, rigorous interpretation, and patient-centered services outperform point solutions in clinical adoption and payer acceptance. Moreover, geographic and regulatory nuances demand tailored approaches rather than one-size-fits-all rollouts, and supply chain dynamics such as tariff changes can materially affect operational viability.

Looking ahead, success will favor organizations that can demonstrate clinical and economic value, maintain flexible and resilient sourcing strategies, and invest in transparent governance to preserve trust. Strategic partnerships and targeted evidence programs will accelerate uptake, while workforce education and clinician engagement will reduce implementation friction. In sum, the pathway to scaling predictive genetics hinges on aligning technological innovation with real-world clinical workflows, reimbursement realities, and responsible data stewardship.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of polygenic risk scoring in routine clinical decision support workflows for chronic disease prevention
  • 5.2. Expansion of direct-to-consumer genetic testing platforms offering ancestry and health risk insights through AI-driven interpretation
  • 5.3. Use of pharmacogenomic profiling to personalize oncology treatment regimens and reduce adverse drug reactions in cancer care
  • 5.4. Advancements in nanopore sequencing enabling real-time pathogen surveillance and outbreak prediction in public health settings
  • 5.5. Strategic partnerships between genomic startups and telemedicine providers to deliver at-home DNA test kits and consultations
  • 5.6. Implementation of GDPR-compliant genomic data sharing frameworks for cross-border research collaborations
  • 5.7. Adoption of blockchain technology to enhance security and transparency in genetic data management and patient consents

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Predictive Genetics Market, by Technology

  • 8.1. Microarray
    • 8.1.1. Comparative Genomic Hybridization
    • 8.1.2. Expression Microarray
  • 8.2. Next Generation Sequencing
    • 8.2.1. Targeted Sequencing
    • 8.2.2. Whole Exome Sequencing
    • 8.2.3. Whole Genome Sequencing
  • 8.3. Polymerase Chain Reaction
    • 8.3.1. Digital PCR
    • 8.3.2. Real Time PCR
  • 8.4. Sanger Sequencing

9. Predictive Genetics Market, by Test Type

  • 9.1. Cancer Screening
    • 9.1.1. BRCA Testing
    • 9.1.2. Colorectal Cancer Screening
    • 9.1.3. Lung Cancer Screening
  • 9.2. Carrier Screening
    • 9.2.1. Expanded Carrier
    • 9.2.2. Single Gene Carrier
  • 9.3. Pharmacogenomics
    • 9.3.1. CYP Testing
    • 9.3.2. Drug Metabolism Testing
  • 9.4. Prenatal Testing
    • 9.4.1. Invasive Prenatal Testing
    • 9.4.2. Non Invasive Prenatal Testing
  • 9.5. Risk Assessment
    • 9.5.1. Cardiovascular Risk
    • 9.5.2. Neurodegenerative Risk

10. Predictive Genetics Market, by Application

  • 10.1. Cardiovascular
    • 10.1.1. Heart Disease
    • 10.1.2. Stroke
  • 10.2. Infectious Diseases
  • 10.3. Neurological Disorders
  • 10.4. Oncology
    • 10.4.1. Breast Cancer
    • 10.4.2. Colorectal Cancer
    • 10.4.3. Lung Cancer
  • 10.5. Rare Diseases

11. Predictive Genetics Market, by End User

  • 11.1. Academic Research Institutes
  • 11.2. Diagnostic Laboratories
  • 11.3. Direct To Consumer
  • 11.4. Hospitals

12. Predictive Genetics Market, by Product Type

  • 12.1. Consumables
  • 12.2. Instruments
  • 12.3. Services
    • 12.3.1. Genetic Counseling
    • 12.3.2. Sequencing Service
      • 12.3.2.1. NGS Service
      • 12.3.2.2. PCR Service
    • 12.3.3. Testing Service
  • 12.4. Software

13. Predictive Genetics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Predictive Genetics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Predictive Genetics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Myriad Genetics, Inc.
    • 16.3.2. Invitae Corporation
    • 16.3.3. Natera, Inc.
    • 16.3.4. 23andMe Holding Co.
    • 16.3.5. Fulgent Genetics, Inc.
    • 16.3.6. Guardant Health, Inc.
    • 16.3.7. Color Health, Inc.
    • 16.3.8. Helix OpCo, Inc.
    • 16.3.9. Gene by Gene, Ltd.
    • 16.3.10. Genomic Prediction, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PREDICTIVE GENETICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS PREDICTIVE GENETICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PREDICTIVE GENETICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. PREDICTIVE GENETICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. PREDICTIVE GENETICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PREDICTIVE GENETICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PREDICTIVE GENETICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PREDICTIVE GENETICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY EXPRESSION MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY EXPRESSION MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY EXPRESSION MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY EXPRESSION MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY EXPRESSION MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY EXPRESSION MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY BRCA TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY BRCA TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY BRCA TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY BRCA TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY BRCA TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY BRCA TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COLORECTAL CANCER SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COLORECTAL CANCER SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COLORECTAL CANCER SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COLORECTAL CANCER SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COLORECTAL CANCER SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COLORECTAL CANCER SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY LUNG CANCER SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY LUNG CANCER SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY LUNG CANCER SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY LUNG CANCER SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY LUNG CANCER SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY LUNG CANCER SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY EXPANDED CARRIER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY EXPANDED CARRIER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY EXPANDED CARRIER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY EXPANDED CARRIER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY EXPANDED CARRIER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY EXPANDED CARRIER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SINGLE GENE CARRIER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SINGLE GENE CARRIER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SINGLE GENE CARRIER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SINGLE GENE CARRIER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SINGLE GENE CARRIER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SINGLE GENE CARRIER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CYP TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CYP TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CYP TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CYP TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CYP TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CYP TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DRUG METABOLISM TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DRUG METABOLISM TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DRUG METABOLISM TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DRUG METABOLISM TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DRUG METABOLISM TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DRUG METABOLISM TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INVASIVE PRENATAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INVASIVE PRENATAL TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INVASIVE PRENATAL TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INVASIVE PRENATAL TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INVASIVE PRENATAL TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INVASIVE PRENATAL TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NON INVASIVE PRENATAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NON INVASIVE PRENATAL TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NON INVASIVE PRENATAL TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NON INVASIVE PRENATAL TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NON INVASIVE PRENATAL TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NON INVASIVE PRENATAL TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR RISK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR RISK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR RISK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR RISK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR RISK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR RISK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEURODEGENERATIVE RISK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEURODEGENERATIVE RISK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEURODEGENERATIVE RISK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEURODEGENERATIVE RISK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEURODEGENERATIVE RISK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEURODEGENERATIVE RISK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY HEART DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY HEART DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY HEART DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY HEART DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY HEART DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY HEART DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY STROKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY STROKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY STROKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIRECT TO CONSUMER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIRECT TO CONSUMER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIRECT TO CONSUMER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIRECT TO CONSUMER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIRECT TO CONSUMER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIRECT TO CONSUMER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY GENETIC COUNSELING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY GENETIC COUNSELING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY GENETIC COUNSELING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY GENETIC COUNSELING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY GENETIC COUNSELING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY GENETIC COUNSELING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SEQUENCING SERVICE, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SEQUENCING SERVICE, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SEQUENCING SERVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 310.